EXOZ

$7.21-0.24 (-3.29%)

Market ClosedAs of Mar 20, 8:00 PM UTC

eXoZymes, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$7.21
Potential Upside
5%
Whystock Fair Value$7.57
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

eXoZymes, Inc. operates as a development stage biotechnology company. The company focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technolo...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$60.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-155.17%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
4.53

Recent News

GuruFocus.com
Nov 14, 2025

EXoZymes Inc (EXOZ) Q3 2025 Earnings Call Highlights: Unlocking Market Opportunities Amid ...

EXoZymes Inc (EXOZ) showcases innovative breakthroughs and strategic partnerships while navigating financial hurdles and regulatory risks.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Sep 10, 2025

Wall Street Set to Open Higher Wednesday as Key Inflation Measure Declines

US stocks look set to open higher in Wednesday's trading session after a key inflation measure unexp

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Simply Wall St.
Sep 8, 2025

Positive week for eXoZymes, Inc. (NASDAQ:EXOZ) institutional investors who control 48% of the company

Key Insights Given the large stake in the stock by institutions, eXoZymes' stock price might be vulnerable to their...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jul 2, 2025

Here's Why We're Watching eXoZymes' (NASDAQ:EXOZ) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.